选择语言

关注公众号

肿瘤坏死因子（TNFs）及其受体（TNFRs）超家族

肿瘤坏死因子（Tumor Necrosis Factors, TNFs）及肿瘤坏死因子受体超家族（Tumor Necrosis Factor-Tumor Necrosis Factor Receptor Superfamily Family，TNFRSF），简称TNF-TNFR家族，是免疫学、细胞生物学及临床医学领域的核心信号分子家族，广泛参与细胞存活、增殖、分化及凋亡（程序性细胞死亡），尤其在炎症反应、免疫调控和组织稳态维持中发挥关键作用，同时与自身免疫病、肿瘤等疾病的发生发展密切相关。

基于其核心的生物学功能与疾病关联机制，TNFSF及TNFRSF家族中的众多成员已成为生物医药领域的重要靶点，临床转化应用成果丰硕。

>>滚动查看

应用领	核心应用方向	代表药物&作用机制
自身免疫病	炎症抑制、B细胞调控、抗纤维化	- 英夫利昔单抗：嵌合型抗TNF-α单抗，特异性结合可溶性与膜结合型TNF-α，阻断其与TNF受体结合，减少促炎细胞因子（如IL-1、IL-6）释放，抑制炎症细胞浸润与组织损伤 - 阿达木单抗：全人源抗TNF-α单抗，持续中和TNF-α，降低滑膜炎症反应，缓解关节损伤 - 依那西普：TNF受体融合蛋白，竞争性结合TNF-α，阻断炎症信号传导，减少炎症介质产生 - 泰它西普：融合蛋白类药物，同时抑制BAFF和APRIL两种B细胞生存因子，减少异常B细胞活化及自身抗体生成，精准调控B细胞免疫失衡
肿瘤治疗	免疫激活、诱导凋亡、精准靶向	- 替伊莫单抗：由抗CD20单抗与连接螯合剂tiuxetan经硫脲共价键结合而成，替伊莫单抗螯合物紧密结合Y-90放射性元素，并与替伊莫单抗共价结合，Y-90释放β射线通过在靶细胞及邻近细胞形成自由基而诱导细胞死亡。
骨代谢疾病	抑制骨吸收、防治骨转移	- 地诺单抗：全人源抗RANKL单抗，结合并阻断RANKL与破骨细胞表面RANK受体的结合，抑制破骨细胞的活化、增殖与存活，从而减少骨吸收，增加骨密度，降低骨相关事件（如骨折、骨痛）及骨转移风险
神经退行性疾病	神经保护、髓鞘再生、减缓疾病进展	- XPro1595：经修饰的可溶性 TNF 抑制剂，可选择性中和可溶性TNF-α，减少神经炎症反应，保护神经元免受损伤；同时不阻断跨膜 TNF-α 信号通路，保留其生理免疫调节功能，降低脱髓鞘风险

T 细胞上的共刺激型肿瘤坏死因子受体超家族（TNFRSF）成员，及其配体和代表性信号通路。
图片来源：doi: 10.1146/annurev-immunol-082423-040557

ACROBiosystems百普赛斯深耕TNF-TNFR家族靶点研发需求，针对性开发全系列产品组合，涵盖

多种属、多标签类型的重组蛋白，其中TNFRSF三聚体结构经MALS验证；
靶点过表达及报告基因细胞株；
ELISA/TR-FRET技术平台抑制剂筛选试剂盒。

该系列产品可用于抗体的免疫制备、中和抗体的快速高通量筛选、细胞学功能验证以及种属交叉反应、信号通路机制研究等多个应用场景，兼容ELISA、SPR、BLI、FACS、AlphaLISA和MSD等多个实验平台，高效赋能TNF-TNFR家族靶向药物的研发与临床转化。

知识补充：蛋白保持正确聚集状态和结构的必要性

TNFRSF家族（OX40L、CD40L、CD27L、4-1BBL、GITRL、CD30L等）在天然状态下常以膜锚定或可溶的三聚体形式存在。

三聚体结构能有效促进和对应的受体结合，进而有效激发下游通路。经天然三聚体结构蛋白免疫所得抗体，能更好的识别天然抗原表位，有效阻断受体和配体结合。

正确折叠的天然构象的靶点蛋白具有良好的生物活性和功能，保证抗体药物研发顺利进行。

靶点蛋白产品特点

高纯度，经MALS/HPLC验证

高生物活性，经ELISA/SPR/FACS等验证

可用于中和抗体验证等多种场景

严格的QC质检保证高批间一致性

产品列表

配体	受体
4-1BB Ligand	4-1BB
APRIL	BCMA
APRIL	TACI
BAFF	BCMA
BAFF	BAFFR
BAFF	TACI
CD27 Ligand	CD27
CD30 Ligand	CD30
CD40 Ligand	CD40
Fas Ligand	Fas
GITR Ligand	GITR
LIGHT	HVEM
LIGHT	LTβR
LT-β	LTβR

配体	受体
LT-α	TNFR1
LT-α	TNFR2
OX40 Ligand	OX40
TNFSF11	RANK
TNFSF11	OPG
TNF-α	TNFR1
TNF-α	TNFR2
TRAIL	TRAIL R3
TRAIL	TRAIL R4
TRAIL	TRAIL R1
TRAIL	TRAIL R2
TL1A	DR3
TWEAK	TWEAK R

验证数据

SEC-MALS验证蛋白的真实分子量和聚体状态

The purity of Human 4-1BB Protein, Mouse IgG2a Fc Tag (Cat. No. 41B-H5256) is more than 85% and the molecular weight of this protein is around 95-125 kDa verified by SEC-MALS.

Report

SEC-MALS验证蛋白的真实分子量和聚体状态

The purity of Human CD27 Ligand Protein, Fc Tag (Cat. No. CDL-H5266) is more than 85% and the molecular weight of this protein is around 160-190 kDa verified by SEC-MALS.

Report

4-1BB蛋白与4-1BBL结合活性经ELISA验证

Immobilized Human 4 1BB Ligand, Fc Tag at 1 μg/mL (100 μL/well) can bind Human 4-1BB Protein, Mouse IgG2a Fc Tag (Cat. No. 41B-H5256) with a linear range of 0.6-5 ng/mL (QC tested).

Protocol

OX40蛋白与OX40L结合活性经ELISA验证

Immobilized Human OX40 Protein, His Tag (Cat. No. OX0-H5224) at 2 μg/mL (100 μL/well) can bind Human OX40 Ligand, Fc Tag, premium grade (Cat. No. OXL-H5266) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

OX40蛋白与OX40L结合亲和力经BLI验证

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand Protein, His Tag (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

BAFF与BCMA高结合亲和力经BLI验证

Loaded Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) on Protein A Biosensor, can bind Biotinylated Human BCMA, His,Avitag (Cat. No. BCA-H82E4) with an affinity constant of 0.69 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

DR3与TL1A结合亲和力经SPR验证

Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) immobilized on CM5 Chip can bind Human TL1A, His Tag (Cat. No. TLA-H5243) with an affinity constant of 45.8 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

CD40与CD40L结合亲和力经SPR验证

Human CD40 Protein, Fc Tag (Cat. No. CD0-H5253) captured on Protein A Chip can bind Human CD40 Ligand, His,Flag Tag, premium grade (Cat. No. CDL-H52Db) with an affinity constant of 1.20 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

LIGHT蛋白诱导HT-29细胞毒性

Human LIGHT Protein, His Tag (Cat. No. LIT-H5242) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.11-3.87 ng/mL (Routinely tested).

Protocol

4-1BBL蛋白诱导HT1080 human CD137细胞系分泌IL-8

Human 4-1BB Ligand (71-254) Protein, His, Flag Tag (Cat. No. 41L-H52D4) induce IL-8 secretion in HT1080 human CD137 cell line. The EC50 for this effect is 0.20-0.44 μg/mL (Routinely tested).

Protocol

TL1A过表达细胞株活性经FACS验证

Expression analysis of human TL1A on HEK293/Human TL1A Stable Cell Line by FACS.Cell surface staining was performed on HEK293/Human TL1A Stable Cell Line (Cat.No. CHEK-ATP142) or negative control cell using anti-human TL1A Antibody followed by staining with PE anti-human IgG Fc Antibody.

Protocol

CD40L过表达细胞株活性经FACS验证

FACS analysis of CD40 Ligand on HEK293/Human CD40 Ligand Stable Cell Line.FACS assay shows that CD40 Ligand Antibody can bind to HEK293/Human CD40 Ligand Stable Cell Line (Cat.No. CHEK-ATP041). HEK293/Human CD40 Ligand Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).

Protocol

使用OX40 [Biotinylated] : OX40L抑制剂筛选试剂盒(Cat. No. EP-162)检测抗OX40L中和抗体对OX40: OX40L结合的抑制效果

INHIBITION OF OX40[Biotinylated]: OX40 Ligand BINDING BY ANTI-OX40 NEUTRALIZING ANTIBODY Serial dilutions of Anti-OX40 Neutralizing antibody (Catalog # EP162-C04) (1:1 serial dilution, from 0.5 μg/mL to 0.0078125 μg/mL) was added into OX40[Biotinylated]: OX40 Ligand binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

Protocol

使用人OX40 / OX40L抑制剂筛选试剂盒 (TR-FRET) (Cat. No. FRT-P014)检测抗OX40L抗体对OX40: OX40L结合的抑制效果

Inhibition of Europium-chelate labeled Human OX40 Ligand protein: FA Labeled Human OX40 Protein binding by Anti-OX40 Antibody Premix serial dilutions of Anti-OX40 Antibody (1:2 serial dilution, from 10 μg/mL to 0.0024 μg/mL (66.67-0.016 nM)) and FA Labeled Human OX40 Protein. Then add Human OX40 Ligand Protein Europium-chelate and incubate at room temperature (20℃-25℃) for 1 hours. Detection was performed with IC50 of 0.7388nM. The assay was performed according to the above-described Datasheet (QC tested).

Protocol